Cargando…

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy

BACKGROUND: PSMA PET/CT visualises prostate cancer residual disease or recurrence at lower PSA levels compared to conventional imaging and results in a change of treatment in a remarkable high number of patients. Radiotherapy with dose escalation to the former prostate bed has been associated with i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt-Hegemann, Nina-Sophie, Fendler, Wolfgang Peter, Ilhan, Harun, Herlemann, Annika, Buchner, Alexander, Stief, Christian, Eze, Chukwuka, Rogowski, Paul, Li, Minglun, Bartenstein, Peter, Ganswindt, Ute, Belka, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833127/ https://www.ncbi.nlm.nih.gov/pubmed/29499730 http://dx.doi.org/10.1186/s13014-018-0983-4

Ejemplares similares

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2017)

Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
por: Schmidt Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design
por: Kretschmer, Alexander, et al.
Publicado: (2021)

Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment
por: Hegemann, Nina-Sophie, et al.
Publicado: (2016)

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy
por: Wenter, Vera, et al.
Publicado: (2017)

Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients
por: Herlemann, Annika, et al.
Publicado: (2017)

A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2021)

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
por: Rogowski, Paul, et al.
Publicado: (2021)

A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy
por: Shi, Run, et al.
Publicado: (2019)

DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score
por: Unger, Kristian, et al.
Publicado: (2023)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Preliminary experience with dosimetry, response and patient reported outcome after (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
por: Fendler, Wolfgang P., et al.
Publicado: (2016)

Total Tumor Volume on (18)F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with (225)Ac-PSMA-I&T
por: Unterrainer, Lena M., et al.
Publicado: (2022)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy
por: Li, Minglun, et al.
Publicado: (2022)

Radiotherapy of oligometastatic prostate cancer: a systematic review
por: Rogowski, Paul, et al.
Publicado: (2021)

Choline PET based dose-painting in prostate cancer - Modelling of dose effects
por: Niyazi, Maximilian, et al.
Publicado: (2010)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Intra-fraction motion of the prostate is not increased by patient couch shifts
por: Ballhausen, Hendrik, et al.
Publicado: (2016)

Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer
por: Shi, Run, et al.
Publicado: (2020)

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
por: Unterrainer, Marcus, et al.
Publicado: (2021)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
por: Spohn, Simon K. B., et al.
Publicado: (2022)

Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort
por: Manapov, Farkhad, et al.
Publicado: (2016)

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Incidental Finding of a PSMA-Positive Pancreatic Cancer in a Patient Suffering from a Metastasized PSMA-Positive Prostate Cancer
por: Sirtl, Simon, et al.
Publicado: (2021)

Occurrence of symptomatic lymphocele after open and robot-assisted radical prostatectomy
por: Magistro, Giuseppe, et al.
Publicado: (2021)

A comparative assessment of prostate positioning guided by three-dimensional ultrasound and cone beam CT
por: Li, Minglun, et al.
Publicado: (2015)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy
por: Spohn, Simon K. B., et al.
Publicado: (2023)

Excellent local control and survival after postoperative or definitive radiation therapy for sarcomas of the head and neck
por: Andrä, Claudia, et al.
Publicado: (2015)

Management of pelvic lymphoceles after radical prostatectomy: A multicentre community based study
por: Khoder, WY, et al.
Publicado: (2011)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy
por: Völter, Friederike, et al.
Publicado: (2021)

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
por: Manapov, Farkhad, et al.
Publicado: (2018)

Radiotherapy in oligometastatic prostate cancer—a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO)
por: Rogowski, Paul, et al.
Publicado: (2022)

Risk of second cancer following radiotherapy for prostate cancer: a population-based analysis
por: Hegemann, Nina-Sophie, et al.
Publicado: (2017)

Maximum standardized uptake value of primary tumor (SUVmax_PT) and horizontal range between two most distant PET-positive lymph nodes predict patient outcome in inoperable stage III NSCLC patients after chemoradiotherapy
por: Roengvoraphoj, Olarn, et al.
Publicado: (2020)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients
por: Niyazi, Maximilian, et al.
Publicado: (2014)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
por: Brosch-Lenz, Julia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fc7ujs5valoa7lgi1k6m17b041